Principal Scientist
Merck & Co., Inc.
West Point, United States
Dr. Ayele is a lead epidemiologist in vaccine epidemiology at Merck Co., Inc., since June 2021. He had been a post-doctoral fellow in the Department of Epidemiology, Biostatistics, and Occupational Health at McGill University and the Lady Davis Institute in Montreal, Canada between December 2016 and June 2021. He has been working on several pharmacoepidemiologic research projects using large population-based data. His previous training includes a Ph.D. study in the Netherlands and a Master of Public Health in Ethiopia. His doctoral training was held at University Medical Center Utrecht, Utrecht University, the Netherlands between 2012 and 2016. He successfully defended his Ph.D. thesis, which examined the effectiveness of isoniazid preventive therapy (IPT) in HIV infected people in Ethiopia. One of his previous significant research contributions is co-leading and coordinating a large cluster-randomized community trial assessing the effectiveness of community-based nurses in improving skill birth attendance in rural Ethiopia with the support of a highly competitive World Health Organization implementation research grant.
Dr. Ayele also made significant leadership contributions including co-founding the College of Health and Medical Sciences at Dilla University (Ethiopia), where he served as Dean of the College from 2008 to 2012. He served as the president (the youngest ever President of the public Universities in Ethiopia) of Dilla University until he started his postdoctoral training in December 2016 at McGill University.
His ultimate career goal is to making an impactful contribution in the development vaccine for the prevention of diseases of high public health importance by generating real-world evidence. His primary responsibility is designing comparative post marketing effectiveness and safety studies using novel pharmacoepidemiologic methods and explore more valid and efficient study designs.
Disclosure information not submitted.
Intermediate/Advanced Topics in Vaccine Safety and Effectiveness
Sunday, August 25, 2024
2:30 PM – 6:00 PM CEST